← 返回专利悬崖列表
CAS 7693-46-1
4-nitrophenyl carbonochloridate
登记编号：EFAV-020、RITO-019、SOLIF-013、AZIL-039
应用背景（按来源药适应症）
HIV感染依非韦伦/拉米夫定/富马酸替诺福韦二吡呋酯慢性丙型肝炎帕利普韦/奥比他韦/利托那韦丙型肝炎帕利普韦/奥比他韦/利托那韦失代偿性肝硬化帕利普韦/奥比他韦/利托那韦肾功能不全帕利普韦/奥比他韦/利托那韦纤维化帕利普韦/奥比他韦/利托那韦终末期肾脏病帕利普韦/奥比他韦/利托那韦HIV感染乙醇达芦那韦/利托那韦下尿路症状琥珀酸索利那新/盐酸坦洛新前列腺增生琥珀酸索利那新/盐酸坦洛新膀胱过度活动症琥珀酸索利那新/盐酸坦洛新药物相关的副作用和不良反应琥珀酸索利那新/盐酸坦洛新膀胱颈梗阻琥珀酸索利那新/盐酸坦洛新高血压阿齐沙坦酯钾盐/氯噻酮原发性高血压阿齐沙坦酯钾盐/氯噻酮HIV感染利托那韦卡波济氏肉瘤利托那韦乳腺癌利托那韦HIV感染依非韦伦克-亚综合征依非韦伦阿尔茨海默病依非韦伦胰腺癌依非韦伦前列腺癌依非韦伦非霍奇金淋巴瘤依非韦伦膀胱过度活动症琥珀酸索利那新急迫性尿失禁琥珀酸索利那新泌尿系疾病琥珀酸索利那新原发性高血压美阿沙坦钾高血压美阿沙坦钾
来源药（使用该中间体的合成路线）
| 品种 | 梯队 | 到期年 |
|---|---|---|
| 依非韦伦/拉米夫定/富马酸替诺福韦二吡呋酯Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate | Tier C · 观察 / 贸易 | - |
| 帕利普韦/奥比他韦/利托那韦Paritaprevir/Ombitasvir/Ritonavir | Tier C · 观察 / 贸易 | - |
| 乙醇达芦那韦/利托那韦Darunavir Ethanolate/Ritonavir | Tier C · 观察 / 贸易 | - |
| 琥珀酸索利那新/盐酸坦洛新Solifenacin Succinate/Tamsulosin Hydrochloride | Tier C · 观察 / 贸易 | - |
| 阿齐沙坦酯钾盐/氯噻酮Azilsartan Medoxomil Potassium/Chlorthalidone | Tier C · 观察 / 贸易 | - |
| 利托那韦Ritonavir | Tier C · 观察 / 贸易 | - |
| 依非韦伦Efavirenz | Tier B · 提前布局 | - |
| 琥珀酸索利那新Solifenacin Succinate | Tier B · 提前布局 | - |
| 美阿沙坦钾Azilsartan Medoxomil Potassium | Tier C · 观察 / 贸易 | - |
合成路线中的位置（上下游链）
按路线登记顺序排列，左→右为合成方向；高亮为当前 CAS，其余可点击跳转对应档案。
ethynylcyclopropane→2-(2-amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluorobut-3-yn-2-ol→5-chloro-2-nitrobenzaldehyde→1-(5-chloro-2-nitrophenyl)-3-cyclopropylprop-2-yn-1-ol→1-(5-chloro-2-nitrophenyl)-3-cyclopropylprop-2-yn-1-one→(1R,2R,4R,5S)-1-(3,5-bis(trifluoromethyl)benzyl)-2-((R)-hydroxy(quinolin-4-yl)methyl)-5-vinylquinuclidin-1-ium bromide→(S)-2-(5-chloro-2-nitrophenyl)-4-cyclopropyl-1,1,1-trifluorobut-3-yn-2-ol→4-nitrophenyl carbonochloridate
(S)-benzyl (1-hydroxy-3-phenylpropan-2-yl)carbamate→(S)-benzyl (1-oxo-3-phenylpropan-2-yl)carbamate→dibenzyl ((2S,3R,4R,5S)-3,4-dihydroxy-1,6-diphenylhexane-2,5-diyl)dicarbamate→1-bromo-2-methyl-1-oxopropan-2-yl acetate→(5S,6R,7R,8S)-5,8-dibenzyl-7-bromo-3,10-dioxo-1,12-diphenyl-2,11-dioxa-4,9-diazadodecan-6-yl acetate→dibenzyl ((1S,1'S)-((2R,3R)-oxirane-2,3-diyl)bis(2-phenylethane-1,1-diyl))dicarbamate→dibenzyl ((2S,3S,5S)-3-hydroxy-1,6-diphenylhexane-2,5-diyl)dicarbamate→(2S,3S,5S)-2,5-diamino-1,6-diphenylhexan-3-ol→phenylboronic acid→(S)-1-((4S,6S)-4-benzyl-2-phenyl-1,3,2-oxazaborinan-6-yl)-2-phenylethanamine→4-nitrophenyl (thiazol-5-ylmethyl) carbonate→thiazol-5-ylmethyl ((2S,3S,5S)-5-amino-3-hydroxy-1,6-diphenylhexan-2-yl)carbamate→(S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanoic acid→ethyl 2-chloroacetate→ethyl 2-chloro-3-oxopropanoate→methanethioamide→ethyl thiazole-5-carboxylate→thiazol-5-ylmethanol→4-nitrophenyl carbonochloridate→isobutyramide→2-methylpropanethioamide→1,3-dichloropropan-2-one→methyl L-valinate hydrochloride→1-(2-isopropylthiazol-4-yl)-N-methylmethanamine→RITO-025→(S)-methyl 2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanoate
(S)-benzyl (1-hydroxy-3-phenylpropan-2-yl)carbamate→(S)-benzyl (1-oxo-3-phenylpropan-2-yl)carbamate→dibenzyl ((2S,3R,4R,5S)-3,4-dihydroxy-1,6-diphenylhexane-2,5-diyl)dicarbamate→1-bromo-2-methyl-1-oxopropan-2-yl acetate→(5S,6R,7R,8S)-5,8-dibenzyl-7-bromo-3,10-dioxo-1,12-diphenyl-2,11-dioxa-4,9-diazadodecan-6-yl acetate→dibenzyl ((1S,1'S)-((2R,3R)-oxirane-2,3-diyl)bis(2-phenylethane-1,1-diyl))dicarbamate→dibenzyl ((2S,3S,5S)-3-hydroxy-1,6-diphenylhexane-2,5-diyl)dicarbamate→(2S,3S,5S)-2,5-diamino-1,6-diphenylhexan-3-ol→phenylboronic acid→(S)-1-((4S,6S)-4-benzyl-2-phenyl-1,3,2-oxazaborinan-6-yl)-2-phenylethanamine→4-nitrophenyl (thiazol-5-ylmethyl) carbonate→thiazol-5-ylmethyl ((2S,3S,5S)-5-amino-3-hydroxy-1,6-diphenylhexan-2-yl)carbamate→(S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanoic acid→ethyl 2-chloroacetate→ethyl 2-chloro-3-oxopropanoate→methanethioamide→ethyl thiazole-5-carboxylate→thiazol-5-ylmethanol→4-nitrophenyl carbonochloridate→isobutyramide→2-methylpropanethioamide→1,3-dichloropropan-2-one→methyl L-valinate hydrochloride→1-(2-isopropylthiazol-4-yl)-N-methylmethanamine→RITO-025→(S)-methyl 2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanoate
(S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline→(R)-quinuclidin-3-ol→4,4,5,5-tetramethyl-2-phenyl-1,3,2-dioxaborolane→ethyl(phenyl)zinc→3,4-dihydroisoquinoline 2-oxide→tert-butyl ((2S,3S)-3-methyl-1-morpholinopentan-2-yl)carbamate→(S)-1-phenyl-3,4-dihydroisoquinolin-2(1H)-ol→4-nitrophenyl carbonochloridate→4-nitrophenyl (S)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate
methyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate→methyl (Z)-2-ethoxy-1-((2'-(N'-hydroxycarbamimidoyl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate→4-(chloromethyl)-5-methyl-1,3-dioxol-2-one→(Z)-2-ethoxy-1-((2'-(N'-hydroxycarbamimidoyl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylic acid→(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (Z)-2-ethoxy-1-((2'-(N'-hydroxycarbamimidoyl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate→4-nitrophenyl carbonochloridate→(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (Z)-2-ethoxy-1-((2'-(N'-(((4-nitrophenoxy)carbonyl)oxy)carbamimidoyl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate
本站可供应的对应中间体
目录暂未收录该靶点的在售中间体 —— 可直接发起询价，需求会进入撮合池。
本页为中间体 CAS 注册档案：同 CAS 的多条路线登记已合并；后续供应商报价与买方需求以该 CAS 为主键撮合。